Abstract-A population-based retrospective chart review of the biochemical liver tests of 844 patients with multiple sclerosis prescribed a ␤-interferon (IFN␤) product in British Columbia, Canada was performed between 1995 and 2001. Overall, 36.9% (243/659) of patients developed new elevations of alanine aminotransferase. All the IFN␤s caused elevated aminotransferase levels compared with pretreatment levels (p Ͻ 0.005) and were higher than reported in clinical trials. Their relative effect on aminotransferases can be approximated as IFN␤-1b(subcutaneous [SC]) ϭ IFN␤-1a(SC) Ͼ IFN␤-1a(IM).
Methods. We report a retrospective review of patients with multiple sclerosis (MS) prescribed an IFN␤ in British Columbia between July 1995 and June 2001 and followed for at least 6 months. The British Columbia population was 4,058,833 in 2000. IFN␤-1b (SC, 250 g alternate days) was licensed July 1995; IFN␤-1a (SC, 22 or 44 g thrice weekly) was licensed February 1998; and IFN␤-1a (IM, 30 g once weekly) was licensed April 1998. Reimbursement of an IFN␤ required a prescription from one of the four MS clinics, patients aged 18 to 60 years with Ն2 relapses in the previous 2 years, and an Expanded Disability Status Scale (EDSS) Յ6.5. Drug costs prohibit most patients from gaining a private prescription outside of the MS clinics. No uniform protocol for liver tests existed during the study period; however, as a minimum, alanine and aspartate aminotransferases (ALT, AST), total bilirubin (Tbili), alkaline phosphatase (AP) and, until 1999, ␥-glutamyltranspeptidase (GGT) were measured before treatment and months 3, 6, 12, and yearly thereafter. Stopping drug because of elevated results was at the physicians' discretion. Patients were free to visit any hospital or community laboratory. For analysis, liver tests were grouped into baseline (up to 6 months pretreatment), months Ͼ0 to 6, months Ͼ6 to 12, and yearly thereafter. When multiple tests were recorded, the highest value was used. Exclusion criteria included previous use of IFN␤ or glatiramer acetate and comorbidity causing pretreatment elevated liver tests. Liver test results were recorded as a fraction of the upper limit of normal (ULN) provided by each laboratory.
Aminotransferases were graded according to the World Health Organization criteria: grade 0 (ՅULN); grade 1 (ϾULN to 2.5 ULN); grade 2 (Ͼ2.5 to 5 ULN); grade 3 (Ͼ5 to 20 ULN); and grade 4 (Ͼ20 ULN).
Statistical analyses were carried out using SPSS (version 10.0, Chicago, IL). A chi-square test compared categorical variables. Kruskall-Wallis test was used for interval results (non-normal), and McNemar test was used for "before-and-after" results. Student's t-test and repeated-measures analysis of variance were used for parametric variables and liver tests over time.
Results. Eight hundred forty-six eligible patients were identified; 844 charts were available for review; and 835 patients had at least one liver test result recorded. There were significant pretreatment differences between the IFN␤ groups (table 1). Mean time on drug for IFN␤-1b(SC) was 29.5 months, IFN␤-1a(SC) 15.7 months, and IFN␤-1a(IM) 14.7 months. The study covered 1,626 treated patient-years.
ALT results are presented in table 2, and AST results are available online (see table E-1 on the Neurology Web site; go to www.neurology.org). There were de novo grade 1, 2, and 3 elevations of ALT and AST in patients treated with IFN␤ (p Ͻ 0.05). IFN␤-1a(SC) (p Ͻ 0.005) and IFN␤-1b(SC) (p Ͻ 0.0005), but not IFN␤-1a(IM) (p Ͼ 0.05), showed grade 2 de novo elevations in aminotransferases. The pattern of elevation differed, peaking within the first 6 months for IFN␤-1b(SC) and IFN␤-1a(SC) and later, between months 6 and 12, for IFN␤-1a(IM) (figure).
Direct dose comparisons of the IFN␤s are difficult. Using the World Health Organization reference standardsavailable from the product information for IFN␤-1a(IM) and IFN␤-1b(SC)-and assuming equal activity between IFN␤-1a preparations, weekly doses approximate as 28 MIU for IFN␤-1b(SC), 26.4 MIU for high-dose IFN␤-1a(SC), 13.2 MIU for low-dose IFN␤-1a(SC), and 6 MIU for Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the February 24 issue to find the title link for this article.
IFN␤-1a(IM).
There was a dose-response effect within the first 6 months and during the entire study for de novo elevated (Նgrade 1) ALT and AST (independent t-test, p Ͻ 0.05). For ALT elevations during the first 6 months, in order of decreasing equivalent doses, proportion of patients affected were 96 of 322 (29.8%), 37 of 124 (29.8%), 32 of 119 (26.9%), and 7 of 52 (13.5%; p ϭ 0.024). There were marginal differences between the high-and low-dose IFN␤-1a(SC) groups, which were not significant for ALT elevations (p Ͼ 0.05). Injection frequency was associated with de novo elevated (Նgrade one) ALT (p ϭ 0.005) and AST (p ϭ 0.001) during the first 6 months and the entire study period (p ϭ 0.018 and p ϭ 0.004).
When gender, disease duration, age at onset and at treatment initiation, and baseline EDSS were investigated as covariates, only gender was a predictor of de novo elevated aminotransferases (p ϭ 0.03). Men were more likely than women to have elevated aminotransferases at baseline (11.5 vs 6.0%; 2 ϭ 6.10; df ϭ 1; p ϭ 0.013) and during treatment (60.6 vs 39.5%; 2 ϭ 6.20; df ϭ 1; p ϭ 0.013). Elevated aminotransferases (Ͼ3 ULN) and Tbili Ͼ1.6 ULN are associated with 10 to 15% mortality. 4 This combination was measured in two patients within one 5 and 27 months of starting an IFN␤. The latter patient recovered subsequently when drug was stopped. Both patients developed jaundice. No other liver-related symptoms were re- IFN␤ ϭ ␤-interferon; SC ϭ subcutaneous; MS ϭ multiple sclerosis; EDSS ϭ Expanded Disability Status Scale. Discussion. Our (IFN␤-1b) results are similar to another postmarketing study (n ϭ 156; 1 year), which found 37.5% of patients with de novo ALT elevations compared with our 38.9%. 6 In contrast, 11% of patients had mild or moderate ALT elevations in the pivotal clinical trial. 1 Similarly, in an IFN␤-1a(SC) trial (n ϭ 356), ALT was increased in 19.6% and 27.2% of patients treated with low and high doses, which are less than the de novo elevations of 33.6% and 38.0% found in our population. 2 "No evidence of liver enzyme elevations" 3 was reported in the pivotal trial of IFN␤-1a(IM) (n ϭ 158), whereas 23.0% in our study developed de novo elevated ALT (p Ͻ 0.005 compared with baseline). To better reflect postmarketing experience, a Food and Drug Administration MedWatch warning has since been issued for IFN␤-1a(im) (March 2003) of "hepatic injury including elevated serum hepatic enzyme levels, some of which have been severe." While clinical trials cannot be expected to detect all adverse effects, interpretation of data is hindered by the vague reporting style and use of qualitative rather than quantitative terminology.
The IFN␤s differ in their dose, route of administration, glycosylation, amino acid sequencing, formulation pH, excipients, manufacturing, and purifying process. Increasing injection frequency and dose had an effect on subsequent elevated aminotransferases in our population. Dose-dependent hepatotoxicity has been reported with other IFN preparations. 7 Also, increasing the injection frequency without increasing the total dose resulted in more patients with hepatitis C developing elevated ALT. 7 Increased time between injections may enable damaged hepatocytes to recover. Drug-induced hepatotoxicity is complex, and the precise mechanism(s) for many drugs is unknown. The fulminant autoimmune hepatitis found may represent a distinct idiosyncratic reaction. 5 Liver pathology in IFN␤-treated patients with MS is largely unknown; one published biopsy report found "marked portal and lobular inflammation. . .hepatocyte necrosis. . .and mild fibrosis." 8 No predictors of IFN␤-induced liver injury were found. The preponderance of men with elevated aminotransferases at baseline and during treatment could reflect individual laboratories, of which there were Ͼ100, not increasing the ULN for men. The demographic differences found between the IFN␤ groups at baseline were not related to subsequent elevated aminotransferases, indicating a negligible effect on results. Other environmental factors, such as concomitant medications, alcohol, and obesity, could compound the risk of IFN␤-induced liver injury. Alcoholic liver disease was unlikely to be an influencing factor in our population because few pa- tients (3%) had an AST-to-ALT ratio Ͼ2. There are no well-documented drug interactions with the IFN␤s, although there is potential because IFN inhibits the cytochrome P450 enzymes. Acetaminophen 9 and IV methylprednisolone 10 in combination with IFN can cause elevated aminotransferases.
Figure. The percentage of interferon (IFN) ␤-treated patients with elevated aminotransferases over time (Նgrade 1). (A) IFN␤-1a(IM). (B) IFN␤-1b(SC). (C) IFN␤-1a(SC
We suggest regular monitoring of the liver tests, particularly during the first year of treatment, although a balance should be found because frequent testing can cause anxiety, pain, inconvenience, and is not without cost. Patients should be aware of hepatic side effects because even rigorous testing can fail to predict acute liver failure.
